

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

DBTRG-05MG

RRID:CVCL_1169

Type: Cell Line

Proper Citation

RRID:CVCL_1169

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1169

Proper Citation: RRID:CVCL_1169

Description: Cell line DBTRG-05MG is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Anaplastic astrocytoma

Defining Citation: [PMID:11668190](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: DBTRG-05MG

Synonyms: DBTRG.05MG, DBTRG05MG, DBTRG

Cross References: CLO:CLO_0002722, CLO:CLO_0002723, EFO:EFO_0002159, CLDB:cl1005, CLDB:cl1006, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2020, BCRC:60380, BioGRID_ORCS_Cell_line:855, BioSample:SAMN03471277, BioSample:SAMN03473317, BioSample:SAMN10988246, cancercellines:CVCL_1169, Cell_Model_Passport:SIDM00867, ChEMBL-Cells:ChEMBL3308485, ChEMBL-Targets:ChEMBL614801, Cosmic:685871, Cosmic:850827, Cosmic:906835, Cosmic:1746961, Cosmic:2302326, Cosmic:2367523, Cosmic:2516015, Cosmic-

CLP:906835, DepMap:ACH-000863, DSMZ:ACC-359, DSMZCellDive:ACC-359, ECACC:93061119, EGA:EGAS00001000978, GDSC:906835, GEO:GSM326248, GEO:GSM886974, GEO:GSM888043, GEO:GSM1669728, GEO:GSM5087478, GEO:GSM5087479, GEO:GSM5087480, GEO:GSM5087481, GEO:GSM5087482, GEO:GSM5087483, IARC_TP53:21300, ICLC:HTL98001, IGRhCellID:DBTRG05MG, LiGeA:CCLE_313, LINCS_LDP:LCL-1349, Pharmacodb:DBTRG05MG_285_2019, PRIDE:PXD022868, PRIDE:PXD030304, Progenetix:CVCL_1169, PubChem_Cell_line:CVCL_1169, Wikidata:Q54828614

ID: CVCL_1169

Record Creation Time: 20220427T215745+0000

Record Last Update: 20260829T232431+0000

Ratings and Alerts

No rating or validation information has been found for DBTRG-05MG.

No alerts have been found for DBTRG-05MG.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yang JT, et al. (2025) Elevated expression and secretion of TGF-?? contribute to Temozolomide resistance in human glioblastoma cells. Cancer cell international, 25(1), 427.

Ayanlaja AA, et al. (2025) Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma. Neuro-oncology advances, 7(1), vda170.

Lad M, et al. (2024) Glioblastoma induces the recruitment and differentiation of dendritic-like "hybrid" neutrophils from skull bone marrow. Cancer cell, 42(9), 1549.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Lai TJ, et al. (2024) Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma. Cancer research communications, 4(7), 1834.

Takaki EO, et al. (2024) A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(16), 3603.

Kumar A, et al. (2022) CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(13), 2898.

Schreck KC, et al. (2021) Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(22), 6197.